USD10
Actions PBYI
À propos de Puma BiotechnologyPuma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
USD10
Actions PBYI
À propos de Puma BiotechnologyPuma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Statistiques
FENÊTRE DE TRADING
Fermé
OUVRE À
Données insuffisantes
Capitalisation boursière
309,33 M $US
PRIX D'OUVERTURE
6,22 $US
BAS (1 an)
2,58 $US
ÉLEVÉ (1 an)
7,68 $US
BAS (24 h)
6,00 $US
ÉLEVÉ (24 h)
6,29 $US
Volume (24 h)
229,73 k $US
27,39 %
Historique des prix
Time | Price | Change |
|---|---|---|
Aujourd'hui | 6,22 $US | |
1 jour | 6,04 $US | |
1 semaine | 6,22 $US | |
1 mois | 5,70 $US | |
1 an | 2,96 $US |